Case Study

Lowering MAb Clinical Trial Material Manufacturing Costs With Protein A Chromatography Resins

Source: Purolite Life Sciences
It is well recognized that the cost of that the use of Protein A chromatography resins in biopharmaceutical manufacturing is substantial. However, a high percentage of clinical projects will fail, resulting in the Protein A resin only being used for a small number of cycles – significantly reducing cost-efficiencies

It is well recognized that the cost of that the use of Protein A chromatography resins in biopharmaceutical manufacturing is substantial. However, a high percentage of clinical projects will fail, resulting in the Protein A resin only being used for a small number of cycles – significantly reducing cost-efficiencies.

One solution to the challenge of inefficient use of Protein A in clinical trial manufacturing was presented in a recent webinar titled, “Reducing MAb Clinical Trial Costs by up to 65% using Different Agarose Protein A Chromatography Resins – A Case Study.” In the webinar, Hans Johansson, Applications Manager, Purolite Life Sciences, presented the results of a case study in which they looked at reducing the cost of clinical trial material manufacturing with the use of purpose designed chromatography resins which can be interchanged between phases, tailoring resin performance and cost efficiencies to the differing requirements of early and late phase clinical trials.